Unveiling the effects of an important class of diabetes drugs

[Northerner]

A research team led by Dana-Farber Cancer Institute and Brigham and Women’s Hospital has uncovered surprising new findings that underscore the role of an important signaling pathway, already known to be critical in cancer, in the development of type 2 diabetes.

Their results, published in the November 17, 2014 online issue of the journal Nature, shed additional light on how a longstanding class of diabetes drugs, known as thiazolidinediones (TZDs), work to improve glucose metabolism and suggest that inhibitors of the signaling pathway — known as the MEK/ERK pathway — may also hold promise in the treatment of type 2 diabetes.

http://www.healthcanal.com/metaboli...-of-an-important-class-of-diabetes-drugs.html

 

[HOBIE]

All good stuff 🙂

 

[bill hopkinson]

A research team led by Dana-Farber Cancer Institute and Brigham and Women’s Hospital has uncovered surprising new findings that underscore the role of an important signaling pathway, already known to be critical in cancer, in the development of type 2 diabetes.
Their results, published in the November 17, 2014 online issue of the journal Nature, shed additional light on how a longstanding class of diabetes drugs, known as thiazolidinediones (TZDs), work to improve glucose metabolism and suggest that inhibitors of the signaling pathway — known as the MEK/ERK pathway — may also hold promise in the treatment of type 2 diabetes.
http://www.healthcanal.com/metaboli...-of-an-important-class-of-diabetes-drugs.html

One of the few licensed MEK drugs for cancer, dabrafenib, has a serious reported side effect that it increases blood glucose, according to the FDA.
TZDs on the other hand, I take one, pioglitazone, have a risk which has to be monitored that they can encourage cancer.
I am not going to hold my breath for this line of research...